3 completed, 3 terminated, 2 recruiting, 1 unknown. 5 Phase 2, 1 Not applicable, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Terminated 3, Completed 1, Recruiting 1 |
| Not applicable | 1 | Unknown 1 |
| Phase 1 | 1 | Recruiting 1 |
| Phase 3 | 1 | Completed 1 |
Follow Sclerosis, Systemic: new trials by email Literature Review of Sclerosis, Systemic trials Research Report on Sclerosis, Systemic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Treatment With Human Umbilical Cord-derived Mesenchymal Stromal Cells in Systemic Sclerosis UCMSC, Placebo - Sclerosis, Systemic, Mesenchymal Stem Cells | Phase 1 / Phase 2 | Recruiting | Marie Hudson, MD | 18 | 2023-01-05 | 2026-02-03 |
| An Open-label Extension Trial of HZNP-HZN-825-301 in Adult Participants With Diffuse Cutaneous Systemic Sclerosis (Diffuse Cutaneous SSc) HZN-825 - Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic | Phase 2 | Terminated | Amgen | 174 | 2022-11-04 | 2026-01-05 |
| Clinical Cohort Study of Systemic Sclerosis Sclerosis, Systemic | Recruiting | Peking University Third Hospital | 150 | 2022-01-01 | 2026-09-23 | |
| A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis HZN-825 BID, Placebo, HZN-825 QD - Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic | Phase 2 | Terminated | Amgen | 301 | 2021-11-05 | 2026-03-20 |
| Effects of FT011 in Systemic Sclerosis FT011, Placebo - Scleroderma, Systemic, Scleroderma, Diffuse | Phase 2 | Completed | Certa Therapeutics | 30 | 2021-07-19 | 2023-12-20 |
| Prevalence of Hyperprolactinemia in Systemic Scleroderma blood test - Sclerosis, Systemic, Scleroderma | Completed | University Hospital, Lille | 71 | 2021-03-01 | 2025-12-23 | |
| Pragmatic Clinical Trials in Scleroderma Interstitial lung disease induction algorithm, Pulmonary arterial hypertension algorithm, Raynaud's phenomenon algorithm - Scleroderma, Systemic, Sclerosis, Systemic | Not applicable | Unknown | University of West London | 400 | 2018-10-01 | 2018-08-06 |
| Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Patients With Systemic Sclerosis With Interstitial Lung Disease Pomalidomide (CC-4047), Placebo - Scleroderma, Systemic, Sclerosis, Systemic | Phase 2 | Terminated | Celgene | 23 | 2012-08-09 | 2023-12-01 |
| A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis Placebo, tocilizumab [RoActemra/Actemra] - Sclerosis, Systemic | Phase 3 | Completed | Hoffmann-La Roche | 87 | 2012-03-01 | 2016-09-23 |
Scleroderma, Systemic (9) · Scleroderma, Diffuse (4) · Hyperprolactinemia (1) · Lung Diseases, Interstitial (1)
Connective Tissue Diseases (9) · Skin Diseases (9) · Skin and Connective Tissue Diseases (9) · Brain Diseases (1) · Central Nervous System Diseases (1) · Endocrine System Diseases (1) · Hyperpituitarism (1) · Hypothalamic Diseases (1) · Lung Diseases (1) · Nervous System Diseases (1) · Pituitary Diseases (1) · Respiratory Tract Diseases (1)
FT011 (1) · Hematologic Tests (1) · pomalidomide (1) · tocilizumab (1)
Amgen (2) · Celgene (1) · Certa Therapeutics (1) · Hoffmann-La Roche (1) · Marie Hudson, MD (1) · Peking University Third Hospital (1) · University Hospital, Lille (1) · University of West London (1)
Spain (4) · Canada (3) · France (3) · Poland (3) · United Kingdom (3) · United States (3) · Australia (2) · Germany (2) · Italy (2) · Serbia (2) · Argentina (1) · Chile (1) · China (1) · Greece (1) · Israel (1)
Darren Kelly, PhD (1) · David Launay, MD,PhD (1) · Marie Hudson, MD (1) · Shimon Korish, MD (1)
PMID 27156934, PMID 29066464, PMID 29781586, PMID 29853453, PMID 29858547, PMID 33294861
2023 (1)